Submitted by Anonymous (not verified) on 29 September 2025 - 8:51
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 19, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 19, Status: Authorised